From CNBC.com…
AstraZeneca’s new antibody therapy reduced the risk of people developing Covid-19 symptoms by 77% in a late-stage trial, putting the drugmaker on track to offer protection to those who respond poorly to vaccines.
The company said on Friday that 75% of the participants in the trial for the therapy – two types of antibodies discovered by Vanderbilt University Medical Center – had chronic conditions including some with a lower immune response to vaccinations.
Similar therapies made with a drug class called monoclonal antibodies which mimic naturally occurring immune system proteins are being developed by Regeneron, Eli Lilly and GlaxoSmithKline with partner Vir.
But AstraZeneca is the first to publish positive Covid prevention data from an antibody trial.